Last reviewed · How we verify
IOBENGUANE SULFATE I 123
At a glance
| Generic name | IOBENGUANE SULFATE I 123 |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2008 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
- Evaluating Myocardial Ischemia in Chest Pain Using Exercise CMR
- The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG (NA)
- Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease (PHASE3)
- Sympathetic Nervous System Modulation in Hypertension (PHASE4)
- Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death
- Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IOBENGUANE SULFATE I 123 CI brief — competitive landscape report
- IOBENGUANE SULFATE I 123 updates RSS · CI watch RSS